Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRD vs VD Consolidation in Multiple Myeloma
NCT00522392Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2007
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 10 years. Started Sep 2007; status: terminated.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00522392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522392.